Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

Kumar Gupta, Anil; Gonzalez‐Rojas, Yaneicy; Stanley Petersen Juárez, Erick; Crespo Casal, Manuel; Moya, Jaynier; R. Falci, Diego; Sarkis, Elias; Solis, Joel; Zheng, Hanzhe; Scott, Nicola; L. Cathcart, Andrea; Parra, Sergio; E. Sager, Jennifer; Austin, Daren; Peppercorn, Amanda; Alexander, Elizabeth; W. Yeh, Wendy; Brinson, Cynthia; Aldinger, Melissa; E. Shapiro, Adrienne; Investigators, COMET-ICE; Free, Almena; Johnson, Kimball; M. Cordasco, Edward; Little, Raymond; Ahsan Bajwa, Ali; Doshi, Ankur; Focil, Augusto; Hussain, Rubaba; Bostick, Greg; Somodevilla, Guillermo; Ali, Hasan; J. Kowalczyk, John; Mittal, Shilpi; Caso, Jorge; Goisse, Marcy; Espinal, Ladynez; Zepeda, Luis; Nguyen, Thinh; Martínez, Luis; Álvarez, Germán; M Pucillo, Ronald; Seep, Michael; Parikh, Naval; Escobar, Victor; Curra, Armando; Dal Maso, Vinicius; F. O’Mahony, John; Ramacciotti, Eduardo; Diaz, Jorge; Giovanni Luz, Kléber; Ruane, Peter; Mochlera, Bharat; Roldan Sanchez, Juan; Hernández, Luís; Tavares Fernandez, Alfredo; Leavitt, Glenn; Azizad, Masoud; Afzal, Haider; Fatakia, Adil; Narejos Pérez, Silvia; Stadnik, Claudio; Gorgos, Linda; Sachdeva, Yessica; Segura, Patricia; Quandros, Carlos; Perry, Russell; Sher, Lawrence

doi:10.1001/jama.2022.2832

Public

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

Published in JAMA • Mar 14, 2022

Authors:

Anil Kumar Gupta

Yaneicy Gonzalez‐Rojas

Erick Stanley Petersen Juárez

Abstract

Importance: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progression. Objective: To evaluate the efficacy and adver...

Subject

Medicine

Placebo

Mechanical ventilation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!